Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

被引:0
|
作者
Fabian Fernandez
Wade Morishita
Elizabeth Zuniga
James Nguyen
Martina Blank
Robert C Malenka
Craig C Garner
机构
[1] Nancy Pritzker Laboratory,Department of Psychiatry and Behavioral Sciences
[2] Stanford University,undefined
来源
Nature Neuroscience | 2007年 / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.
引用
收藏
页码:411 / 413
页数:2
相关论文
共 50 条
  • [1] Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
    Fernandez, Fabian
    Morishita, Wade
    Zuniga, Elizabeth
    Nguyen, James
    Blank, Martina
    Malenka, Robert C.
    Garner, Craig C.
    NATURE NEUROSCIENCE, 2007, 10 (04) : 411 - 413
  • [2] Environmental therapy for cognitive and sensory impairment in a mouse model of Down syndrome
    Begenisic, T.
    Baroncelli, L.
    Braschi, C.
    Spolidoro, M.
    Milanese, M.
    Bonanno, G.
    Cioni, G.
    Maffei, L.
    Sale, A.
    INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 2012, 85 (03) : 310 - 311
  • [3] Evidence of Mitochondrial Impairment in a Mouse Model of Down Syndrome
    Anyaoku, Cynthia
    DeRuisseau, Lara R.
    Brandauer, Josef
    FASEB JOURNAL, 2022, 36
  • [4] Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome
    Bianchi, Patrizia
    Ciani, Elisabetta
    Guidi, Sandra
    Trazzi, Stefania
    Felice, Daniela
    Grossi, Gabriele
    Fernandez, Mercedes
    Giuliani, Alessandro
    Calza, Laura
    Bartesaghi, Renata
    JOURNAL OF NEUROSCIENCE, 2010, 30 (26): : 8769 - 8779
  • [5] Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
    Hamlett, Eric D.
    Boger, Heather A.
    Ledreux, Aurelie
    Kelley, Christy M.
    Mufson, Elliott J.
    Falangola, Maria F.
    Guilfoyle, David N.
    Nixon, Ralph A.
    Patterson, David
    Duval, Nathan
    Granholm, Ann-Charlotte E.
    CURRENT ALZHEIMER RESEARCH, 2016, 13 (01) : 35 - 52
  • [6] Kinase activity modulation to restore cognitive impairment and prevent neurodegeneration in a mouse model of down's syndrome
    Solarz, S. C.
    Dierssen, M.
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 195 - 195
  • [7] Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model
    Guidi, Sandra
    Stagni, Fiorenza
    Bianchi, Patrizia
    Ciani, Elisabetta
    Giacomini, Andrea
    De Franceschi, Marianna
    Moldrich, Randal
    Kurniawan, Nyoman
    Mardon, Karine
    Giuliani, Alessandro
    Calza, Laura
    Bartesaghi, Renata
    BRAIN, 2014, 137 : 380 - 401
  • [8] Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model
    Stringer, Megan
    Abeysekera, Irushi
    Dria, Karl J.
    Roper, Randall J.
    Goodlett, Charles R.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2015, 138 : 70 - 79
  • [9] Genes contributing to brain and cognitive impairment of mouse models for trisomy 21 (Down syndrome)
    Roubertoux, Pierre L.
    Carlier, Michele
    BEHAVIOR GENETICS, 2010, 40 (06) : 811 - 812
  • [10] The effects of piracetam on cognitive performance in a mouse model of Down's syndrome
    Moran, TH
    Capone, GT
    Knipp, S
    Davisson, MT
    Reeves, RH
    Gearhart, JD
    PHYSIOLOGY & BEHAVIOR, 2002, 77 (2-3) : 403 - 409